US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bayer A.G.

7.59

+0.06900.92%

Post-market: 7.590.00000.00%16:11 EDT

Volume:837.03K

Turnover:6.31M

Market Cap:29.83B

PE:-8.46

High:7.60

Open:7.48

Low:7.46

Close:7.52

Loading ...

Overview Company News Filings

German Stocks Pare Back Gains After Lawmakers Approve Spending Package -- Market Talk

Bayer Gets Speedy FDA Review of Kerendia in Heart Failure

Bayer treatment of NSCLC granted orphan designation

Bayer price target raised to EUR 26 from EUR 22 at Berenberg

Bayer's Partial Recovery Is in Sight -- Market Talk

Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?

Bayer to Seek Shareholder Approval to Issue Shares Toward U.S. Litigation if Needed

Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More

Bayer CEO: 2025 Will Be 'Most Difficult' Year In Turnaround Plan, Expects Improved Performance From 2026 Onwards

Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk

Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk

Bayer Q4 Adj $0.28 Misses $1.00 Estimate, Sales $12.52B Beat $11.30B Estimate

Bayer Consensus Unlikely to Change Much After Earnings -- Market Talk

Bayer Warns of Lower Earnings as Turnaround Continues -- Update

Bayer's Cash Flow Guidance Looks Soft -- Market Talk

Bayer Earnings, Sales Expected to Fall -- Earnings Preview

Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus

European Pharma Companies to Report 4Q Results With U.S Policy Uncertainty in Focus -- Sector Preview

German stocks are quietly rallying. An election's coming up.

Bayer sees new drugs boosting return to growth in 2027, WSJ reports

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BAYRY/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BAYRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","market":"US","secType":"STK","nameCN":"Bayer A.G.","latestPrice":7.59,"timestamp":1749240000000,"preClose":7.521,"halted":0,"volume":837032,"hourTrading":{"tag":"盘后","latestPrice":7.59,"preClose":7.59,"latestTime":"16:11 EDT","volume":549,"amount":4166.91,"timestamp":1749240699960},"delay":15,"floatShares":3929259738,"shares":3929696328,"eps":-0.897103,"marketStatus":"Not Yet Opened","change":0.069,"latestTime":"06-06 16:00:00 EDT Delay","open":7.48,"high":7.6,"low":7.46,"amount":6313842.425099995,"amplitude":0.018615,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.897103,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":0,"adr":0,"adrRate":0.25,"exchange":"OTCQX","adjPreClose":7.521,"volumeRatio":1.614050378597038},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","floatShares":3929259738,"roa":"2.55%","roe":"-9.49%","lyrEps":-0.672343,"volumeRatio":1.614050378597038,"shares":3929696328,"dividePrice":0.031411,"high":7.6,"amplitude":0.018615,"preClose":7.521,"low":7.46,"week52Low":4.79,"pbRate":"0.80","psRate":"0.56","week52High":8.58,"institutionHeld":0,"latestPrice":7.59,"eps":-0.897103,"divideRate":0.004138,"volume":837032,"delay":15,"ttmEps":-0.897103,"open":7.48,"prevYearClose":4.88,"prevWeekClose":7.07,"prevMonthClose":7.07,"prevQuarterClose":6.02,"fiveDayClose":7.07,"twentyDayClose":6.64,"sixtyDayClose":6.26},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BAYRY\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520260213","title":"German Stocks Pare Back Gains After Lawmakers Approve Spending Package -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2520260213","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520260213?lang=en_us&edition=fundamental","pubTime":"2025-03-18 23:26","pubTimestamp":1742311560,"startTime":"0","endTime":"0","summary":"1526 GMT - German stocks pare back the day's gains after lawmakers approved a major spending plan aimed at turbocharging its military and retooling its stagnating economy. Germany's DAX, the country's blue-chip index, is up 0.7% at 23320.85, having hit a new record high of 23476.01 earlier in the session. Defense company Rheinmetall tops the DAX gainers, up 4.2%, followed by agricultural and pharmaceutical group Bayer, which rises 3.9%. The MDAX index of midcap stocks is up 1.2%, while the SDAX index of small companies climbs 2.3%. \"In our view, this is a historic fiscal regime shift, arguably the largest since German reunification,\" Deutsche Bank Research's Robin Winkler says.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2520254320","title":"Bayer Gets Speedy FDA Review of Kerendia in Heart Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2520254320","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520254320?lang=en_us&edition=fundamental","pubTime":"2025-03-17 18:36","pubTimestamp":1742207760,"startTime":"0","endTime":"0","summary":"Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure.Bayer on Monday said the application covers Kerendia for the treatment of adults with heart failure with a left ventricular ejection fraction, or LVEF, of at least 40%, also known as mildly reduced or preserved LVEF.The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.German drugs-to-crops giant Bayer said about 6.7 million adults in the U.S. live with heart failure, with roughly 55% having mildly reduced or preserved LVEF.The FDA approved Kerendia in 2021 to improve cardiovascular outcomes for patients with type 2 diabetes and chronic kidney disease. The drug generated sales of around $500 million last year.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Bayer Gets Speedy FDA Review of Kerendia in Heart Failure","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":1},{"id":"2518798047","title":"Bayer treatment of NSCLC granted orphan designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2518798047","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518798047?lang=en_us&edition=fundamental","pubTime":"2025-03-12 03:00","pubTimestamp":1741719628,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) HealthCare Pharmaceuticals was granted FDA orphan designation for a treatment of non-small cell lung cancer harboring epidermal growt...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-treatment-of-nsclc-granted-orphan-designation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-treatment-of-nsclc-granted-orphan-designation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2518472148","title":"Bayer price target raised to EUR 26 from EUR 22 at Berenberg","url":"https://stock-news.laohu8.com/highlight/detail?id=2518472148","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518472148?lang=en_us&edition=fundamental","pubTime":"2025-03-11 23:45","pubTimestamp":1741707937,"startTime":"0","endTime":"0","summary":"Berenberg raised the firm’s price target on Bayer (BAYRY) to EUR 26 from EUR 22 and keeps a Hold rating on the shares. Published first on TheFly – ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-price-target-raised-to-eur-26-from-eur-22-at-berenberg?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-price-target-raised-to-eur-26-from-eur-22-at-berenberg?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2518218044","title":"Bayer's Partial Recovery Is in Sight -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2518218044","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518218044?lang=en_us&edition=fundamental","pubTime":"2025-03-10 16:38","pubTimestamp":1741595880,"startTime":"0","endTime":"0","summary":"0838 GMT - Bayer's prospects are improving, Berenberg analyst Sebastian Bray says in a note, citing a promising late-stage stroke prevention trial. Although the German pharmaceutical and agricultural conglomerate's late-stage trial for secondary stroke prevention is considered a long shot, there is a possibility of unexpected upside by the year end if the treatment proves significantly better than the placebo, the analyst says. \"We believe there is an outside chance of a positive outcome for Bayer that may move the market's view of annual peak sales for the drug from very little to 1 billion euros or more,\" he says. In addition, if a Russia-Ukraine peace agreement doesn't cause a major drop in soft commodity prices, Bayer's earnings are unlikely to significantly decrease further, the analyst adds. Shares are up 1.7% at 23.65 euros. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2517581114","title":"Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517581114","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517581114?lang=en_us&edition=fundamental","pubTime":"2025-03-07 22:40","pubTimestamp":1741358405,"startTime":"0","endTime":"0","summary":"The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Bayer Aktiengesellschaft  been one of those stocks this year?A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Bayer Aktiengesellschaft is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.Over the past three months, the Zacks Consensus Estimate for BAYRY's full-year earnings has moved 0.6% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.Over the past three months, AbbVie's consensus EPS estimate for the current year has increased 1%. The stock currently has","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bayer-bayry-outperforming-other-medical-144005468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABBV","BAYRY"],"gpt_icon":0},{"id":"2517143614","title":"Bayer to Seek Shareholder Approval to Issue Shares Toward U.S. Litigation if Needed","url":"https://stock-news.laohu8.com/highlight/detail?id=2517143614","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517143614?lang=en_us&edition=fundamental","pubTime":"2025-03-07 22:12","pubTimestamp":1741356720,"startTime":"0","endTime":"0","summary":"Bayer plans to seek shareholder approval at its upcoming annual general meeting to issue up to 35% of its issued share capital in the event it needs to raise urgent cash toward litigation in the U.S.The pharmaceutical and agricultural conglomerate said Friday that it has no specific plans to utilize the capital request. It added that following feedback from shareholders, it won't use the authority to fund mergers and acquisitions.\"We commit that the proceeds of any issuance would be used solely to maintain balance-sheet resilience while resolving litigation, and not to finance external growth such as M&A transactions,\" Bayer said.It added that any share issues would be carefully evaluated to ensure they benefit shareholders.Bayer remains embroiled in legal battles stemming from its Monsanto business, as plaintiffs blame its Roundup weedkiller for causing cancers--something the company denies. The $63 billion acquisition of Monsanto in 2018 was designed to turn the inventor of aspirin i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bayer to Seek Shareholder Approval to Issue Shares Toward U.S. Litigation if Needed","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2517643107","title":"Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2517643107","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517643107?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:09","pubTimestamp":1741352940,"startTime":"0","endTime":"0","summary":"This week, Bayer BAYRY announced its fourth-quarter and full-year 2024 results. AbbVie ABBV announced a licensing deal with Danish firm Gubra for an amylin-targeting obesity treatment, which marked the company’s entry into the obesity space. Novo Nordisk NVO announced that it is cutting the price of its popular obesity injection, Wegovy, for the uninsured following a similar move byrival Eli Lilly. J&J JNJ discontinued a phase III study on a candidate being evaluated as an adjunctive treatment for major depressive disorder . The FDA accepted Roche’s RHHBY application seeking expanded use of its lymphoma drug, Gazyva/Gazyvaro, for the treatment of lupus nephritis.Here's a recap of the week’s most important stories.Novo Nordisk is launching a new direct-to-patient online pharmacy called NovoCare, which will offer Wegovy at a discounted price of $499 per month, less than half of its listed price. This offer is for patients who do not have insurance coverage and pay by cash as well as thos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-bayrys-q4-130900621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1221951129.SGD","BAYRY","LU2087621335.USD","BK4007","BK4581","LU0912757837.SGD","LU0949170772.SGD","IE00B3PB1722.GBP","ABBV","IE0004445239.USD","LU2347655156.SGD","JNJ","LU1551013425.SGD","LU0795875169.SGD","LU0211327993.USD","LU2237443465.HKD","IE0002141913.USD","SG9999015945.SGD","LU2505996509.AUD","LU1093756325.SGD","BK4592","LU0545039389.USD","IE00B2B36J28.USD","LU1066053197.SGD","BK4585","LU1732800096.USD","LU1261432733.SGD","SG9999011175.SGD","LU0098860793.USD","LLY","LU0553294199.USD","LU1267930490.SGD","IE00BJJMRZ35.SGD","LU1003077747.HKD","LU1914381329.SGD","IE00B42XCP33.USD","LU1196500208.SGD","NVO","LU0689472784.USD","BK4533","IE00BJT1NW94.SGD","LU0234572021.USD","LU0965509010.AUD","LU1989771016.USD","IE00BDGV0183.EUR","LU0965508806.USD","03165","LU1718418525.SGD","BK4566","RHHBY","IE00B1BXHZ80.USD"],"gpt_icon":1},{"id":"2517944924","title":"Bayer CEO: 2025 Will Be 'Most Difficult' Year In Turnaround Plan, Expects Improved Performance From 2026 Onwards","url":"https://stock-news.laohu8.com/highlight/detail?id=2517944924","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517944924?lang=en_us&edition=fundamental","pubTime":"2025-03-06 00:52","pubTimestamp":1741193552,"startTime":"0","endTime":"0","summary":"Bayer reported Q4 adjusted EPS of $0.28, missing estimates, but sales beat forecasts. The company sees 2025 as a tough year, with growth expected from 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/03/44146075/bayer-ceo-2025-will-be-most-difficult-year-in-turnaround-plan-expects-improved-performance-from-2026-onwards","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2517121169","title":"Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2517121169","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517121169?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:39","pubTimestamp":1741181940,"startTime":"0","endTime":"0","summary":"1339 GMT - - Bayer reported fourth-quarter results that were generally above Barclays's forecasts while 2025 group guidance for sales also came in slightly better at the midpoint. The midpoint of the Ebitda target was marginally above the bank's expectations, though free cash flow guide was set lower than Barclays's views, it says. The U.K. bank expects the focus of the company's earnings call to include the potential impact of tariffs, particularly on crop science, and free cash flow over the next couple of years. The bank had been forecasting free cash flow of 2.6 billion euros or 2025 versus company guidance of 1.5 billion to 2.5 billion euros. Barclays has an equal weight rating and 22 euro price target on the stock. Shares rise 3.1% at 24.25 euros. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2517147219","title":"Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2517147219","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517147219?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:26","pubTimestamp":1741181160,"startTime":"0","endTime":"0","summary":"1326 GMT - Bayer's fourth-quarter results showed some positive surprises, but challenges to the company's underlying performance remain, Deutsche Bank analysts write. Fourth quarter sales, adjusted EBITDA and adjusted EPS exceeded expectations, largely due to slightly better-than-expected sales in all three units, along with lower corporate costs. However, underlying results reveal a different picture, with flat organic sales, a 22% decline in adjusted EBITDA and a 43% drop in adjusted EPS. 2025 guidance is not particularly encouraging, but the company's longer-term outlook and plans to address key issues offer some hope for future improvement, they add. \"Investors will likely need to exercise patience as these measures take time to yield results.\" Deutsche Bank has a hold rating and 23 euro target price for Bayer's shares. Shares rise 3.5% at 24.35 euros. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","ISBC"],"gpt_icon":0},{"id":"2517990935","title":"Bayer Q4 Adj $0.28 Misses $1.00 Estimate, Sales $12.52B Beat $11.30B Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2517990935","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517990935?lang=en_us&edition=fundamental","pubTime":"2025-03-05 19:13","pubTimestamp":1741173192,"startTime":"0","endTime":"0","summary":"Bayer (OTC:BAYRY) reported quarterly earnings of $0.28 per share which missed the analyst consensus estimate of $1.00 by 72 percent. This is a 44 percent decrease over earnings of $0.50 per share from the same period","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44136854/bayer-q4-adj-0-28-misses-1-00-estimate-sales-12-52b-beat-11-30b-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bayer Q4 Adj $0.28 Misses $1.00 Estimate, Sales $12.52B Beat $11.30B Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY"],"gpt_icon":1},{"id":"2517999758","title":"Bayer Consensus Unlikely to Change Much After Earnings -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2517999758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517999758?lang=en_us&edition=fundamental","pubTime":"2025-03-05 17:40","pubTimestamp":1741167600,"startTime":"0","endTime":"0","summary":"0940 GMT - Bayer's fourth-quarter results beat sales and Ebitda expectations, Morgan Stanley analysts write. However, guidance came broadly in line, so limited changes to consensus estimates are expected, they add. By division, 2025 crop science and pharma guidance implies around 2% and 4% downside risk to divisional consensus Ebitda estimates, respectively, they say. There was limited updates on litigation, with Bayer confirming that it will file a petition for review with the U.S. Supreme Court on glyphosate claims. Meanwhile, a ruling from the Washington Supreme Court for the Erickson case--which relates to claims of personal injury related to alleged PCB exposure--is expected in the coming months. Shares rise 5.3%. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY"],"gpt_icon":0},{"id":"2517998487","title":"Bayer Warns of Lower Earnings as Turnaround Continues -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2517998487","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517998487?lang=en_us&edition=fundamental","pubTime":"2025-03-05 16:30","pubTimestamp":1741163400,"startTime":"0","endTime":"0","summary":"Bayer guided for lower earnings this year as it continues to work through a turnaround plan, but said performance is expected to improve from 2026.The pharmaceutical and agricultural conglomerate said all three of its business units have attractive long-term prospects, but that it must first steer them through a challenging period ahead before it can take advantage of any opportunities.\"It is the second year in Bayer's turnaround and will be the most difficult in terms of financial performance,\" the German company said Wednesday.Bayer also launched a multi-year plan to improve earnings at its crop-science business.Chief Executive Bill Anderson last year ruled out a breakup of the group into separate units, instead embarking on a 24 to 36 month plan to focus on building a strong pharmaceuticals pipeline, address U.S. legal cases over weedkiller Roundup, reduce debt, and implement a new operating model to improve performance. The crop-science plan announced Wednesday adds to those strate","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY"],"gpt_icon":0},{"id":"2517998434","title":"Bayer's Cash Flow Guidance Looks Soft -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2517998434","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517998434?lang=en_us&edition=fundamental","pubTime":"2025-03-05 16:30","pubTimestamp":1741163400,"startTime":"0","endTime":"0","summary":"0830 GMT - Bayer's fourth-quarter results are slightly ahead of expectations and guidance is in line with consensus, but the free cash flow outlook is soft, Jefferies analysts write. Bayer reported fourth-quarter adjusted Ebitda of 2.35 billion euros versus consensus at 2.27 billion euros while free cash flow also beat views. Full-year 2025 guidance for Ebitda of 9.3 billion-9.8 billion euros at closing exchange rates compares to consensus at 9.4 billion euros while core EPS guidance is also ahead. But free cash-flow guidance of 1.3 billion-2.3 billion euros is below the 2.8 billion euros expected by consensus. \"We expect a small negative response.\" Shares rise 1.5% after initially dropping as much as 2.5% at the open. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2516675458","title":"Bayer Earnings, Sales Expected to Fall -- Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2516675458","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516675458?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:46","pubTimestamp":1741092360,"startTime":"0","endTime":"0","summary":"Bayer is scheduled to report results for the fourth quarter on Wednesday. Here is what you need to know.SALES FORECAST: The German pharmaceutical and agricultural conglomerate is expected to post sales of 11.26 billion euros  for the quarter ended December, according to a Vara Research consensus. The forecast is below sales of 11.86 billion euros Bayer reported for the same quarter the previous year.PROFIT FORECAST: Net profit is forecast to come in at 463 million euros, according to the consensus, down from 1.34 billion euros in the year-earlier period. Earnings before interest, taxes, depreciation, amortization and special items--a metric closely watched by analysts and investors--are expected to fall to 2.27 billion euros from 3.02 billion euros, according to the same consensus.Shares in Bayer fell 36% during the fourth quarter, but have risen 23% since the beginning of 2025.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY"],"gpt_icon":0},{"id":"2516330551","title":"Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516330551","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516330551?lang=en_us&edition=fundamental","pubTime":"2025-03-01 02:14","pubTimestamp":1740766440,"startTime":"0","endTime":"0","summary":"Cytokinetics, Incorporated CYTK reported a net loss of $1.26 per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.22. In the year-ago quarter, the company reported a net loss of $1.38 per share.Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Revenues totaled $16.9 million, which missed the Zacks Consensus Estimate of $20 million. The top line was up from $1.7 million recorded in the year-ago quarter.Total revenues in fourth-quarter and full-year 2024 benefited from a $15.0 million upfront milestone payment from Corxel Pharmaceuticals.Since the company does not have any approved product in its portfolio yet, it does not generate drug sales.Cytokinet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytokinetics-q4-loss-wider-expected-181400233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNY","BAYRY","BK4531","BK4585","BK4139","BK4007","CYTK","HCM","BK4588","IE00BFXG1179.USD","BK4505"],"gpt_icon":0},{"id":"2506264443","title":"European Pharma Companies to Report 4Q Results With U.S Policy Uncertainty in Focus -- Sector Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2506264443","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506264443?lang=en_us&edition=fundamental","pubTime":"2025-01-27 17:00","pubTimestamp":1737968400,"startTime":"0","endTime":"0","summary":"European pharmaceutical companies start to report results for the fourth quarter this week. Analysts anticipate that remarks from executives on pipeline progress and the new U.S. administration, which could review vaccine mandates, will be the recurring themes when companies report earnings for the last quarter of 2024. Here is what you need to know>. Pharma stocks have underperformed the market in the fourth quarter with the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--down 9.4% against a 2.2% fall for the broader Stoxx Europe 600 index over the same period. Chinese market volatility and the new U.S. administration have negatively weighed on selected share prices, especially those with vaccines exposure, Berenberg analysts say.--  Analysts and investors will look at what guidance the major EU pharma companies will set for 2025 as all of them expect key results for potential blockbuster drugs toward the second half of the year","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","BK4599","AZN","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4585","IE00BKVL7J92.USD","IE00BFXG1179.USD","LU1093756325.SGD","IE00BJJMRZ35.SGD","LU2417539215.USD","LU0109394709.USD","IE00B2B36J28.USD","BK4578","LU0154236417.USD","BK4007","LU0211331839.USD","LU2236285917.USD","BK4532","GSK.UK","LU2462157665.USD","BK4588","LU0889565916.HKD","IE0009355771.USD","IE00BJT1NW94.SGD","LU1093756168.USD","MKKGY","LU2456880835.USD","NVO","BAYRY","NVS","RHHBY","BK4568","LU1829250122.USD","SNY","03165","IE0002141913.USD","IE00BFTCPJ56.SGD"],"gpt_icon":1},{"id":"2504415147","title":"German stocks are quietly rallying. An election's coming up.","url":"https://stock-news.laohu8.com/highlight/detail?id=2504415147","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504415147?lang=en_us&edition=fundamental","pubTime":"2025-01-17 20:09","pubTimestamp":1737115740,"startTime":"0","endTime":"0","summary":"German stocks have been the stars of the young new year, ripping higher on Friday to a fresh record high.The gains come amid a weak backdrop for the country - cheap Russian gas that fueled its industrial base has been cut off, the key export market of China is stagnating and domestic demand has been faltering.Last month, the Ifo business climate index, a closely watched economic gauge, fell to the lowest level since May 2020.\"Despite highly volatile interest rate expectations, the DAX continues to take in the mountain air and investors are visibly comfortable at the new level of 20,700 points,\" said Jochen Stanzl, chief market analyst at CMC Markets.The latest YouGov poll shows the CDU/CSU alliance at 30%, the far-right AfD party backed by Elon Musk at 21%, and the SPD at 18%.Commerzbank  and Deutsche Bank  shares have each rallied 11%, but the gains are broad based. Bayer , still reeling from one of the worst-ever M&A transactions when it bought Monsanto, has gained 9% this year.Micro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BAYRY","BK4552","BK4118","BK4011","BK4207","IFNNY","BK4023","SAP","BK4007","DB","BK4528","BK4141","BK4585","BK4566","HDLMY","CRZBY"],"gpt_icon":0},{"id":"2503383796","title":"Bayer sees new drugs boosting return to growth in 2027, WSJ reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2503383796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503383796?lang=en_us&edition=fundamental","pubTime":"2025-01-15 06:30","pubTimestamp":1736893817,"startTime":"0","endTime":"0","summary":"Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid generic ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-sees-new-drugs-boosting-return-to-growth-in-2027-wsj-reports?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-sees-new-drugs-boosting-return-to-growth-in-2027-wsj-reports?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAYRY","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":65,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BAYRY\",params:#limit:5,,,undefined,":[{"date":"2025-08-06","symbol":"BAYRY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1754467200000,"name":null,"time":"","dateTimestamp":1754452800000,"actualEps":null},{"market":"US","date":"2025-05-13","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"","actualEps":null},{"date":"2025-04-29","symbol":"BAYRY","amount":0.030365,"announcedDate":"2025-04-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-29","defaultRemindTime":1745933400000,"name":"Bayer A.G.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-04-29","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-05-12"},{"market":"US","date":"2024-11-12","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"","actualEps":null},{"date":"2024-08-06","symbol":"BAYRY","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722974400000,"name":null,"time":"Post Market","dateTimestamp":1722916800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BAYRY\",market:\"US\",,,undefined,":[{"executeDate":"2016-04-27","recordDate":"2016-04-29","paymentDate":"2016-05-12","value":2.091196,"currency":"USD"},{"executeDate":"2019-04-29","recordDate":"2019-04-30","paymentDate":"2019-05-13","value":0.550569,"currency":"USD"},{"executeDate":"2020-04-29","recordDate":"2020-04-30","paymentDate":"2020-05-14","value":0.535933,"currency":"USD"},{"executeDate":"2021-04-28","recordDate":"2021-04-29","paymentDate":"2021-05-10","value":0.407111,"currency":"USD"},{"executeDate":"2022-05-02","recordDate":"2022-05-03","paymentDate":"2022-05-16","value":0.549114,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BAYRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":2,"updateTime":1746244800000}}}